Skip to main content

Viktor Grünwald

Contact

address:

University-Hospital Essen, Essen, Germany

Viktor Grünwald is a professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in Essen, Germany. 

Professor Grünwald specialises in Internal Medicine and Medical Oncology. His main areas of research interest are in GU cancers, soft tissue sarcomas, head and neck cancers, with an emphasis on the academic development and translational research of immunotherapies inthese indications.

Professor Grünwald graduated from the Medical School Hannover in 1998, after which he was appointed as a Private Lecturer and later professor for Haematology and Oncology at the same institution. He became professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in 2018, thereby chairing the section for medical treatments of GU cancers.

Professor Grünwald served at the steering committee for genitourinary (GU) cancers (non-prostate) at the ESMO and ESMO ASIA Congress and was part of scientific committees of the International Kidney Cancer Symposium (EIKCS), German Cancer Congress (DKK) and the German Society for Haematology and Oncology (DGHO). He has chaired different working groups in academic organizations, such as the Central European Society of Anticancer Drug Research (CESAR) studies group, German Medical Oncology studies group (AIO) and German Cancer Society (DKG). His training activities include ESMO preceptorships and the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research (MCCR).

print
PRINT

Latest contributions from Viktor Grünwald

Expert discussion: Metastatic RCC updates from ASCO GU 2020

25-02-2020 | Renal cell carcinoma | Conference coverage | Video

Metastatic RCC updates from ASCO GU 2020

Bernard Escudier and Viktor Grünwald take us through the metastatic renal cell carcinoma studies that caught their attention at the 2020 Genitourinary Cancers Symposium, including long-term data from the CheckMate 214 trial and studies of novel agents such as the HIF-2α inhibitor MK-6482 and sitravatinib.

This independent video was supported by an educational grant from Pfizer and Merck KGaA.